A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254
| العنوان: | A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254 |
|---|---|
| المؤلفون: | Richard R. Furman, Michael L. Grossbard, Jeffrey L. Johnson, Andrew L. Pecora, Peter A. Cassileth, Sin-Ho Jung, Bruce A. Peterson, Lee M. Nadler, Arnold Freedman, Ruthee-Lu Bayer, Nancy L. Bartlett, David D. Hurd, Bruce D. Cheson, null For The Cancer Leukemia Group B And |
| المصدر: | Leukemia & Lymphoma. 52:587-596 |
| بيانات النشر: | Informa UK Limited, 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Immunoconjugates, Lymphoma, B-Cell, Transplantation Conditioning, Adolescent, medicine.medical_treatment, Ricin, Transplantation, Autologous, Article, Young Adult, Adjuvants, Immunologic, Immunotoxin, Internal medicine, medicine, Adjuvant therapy, Humans, Survival analysis, Aged, Bone Marrow Transplantation, Chemotherapy, business.industry, Immunotoxins, Cancer, Hematology, Middle Aged, medicine.disease, Antibodies, Neutralizing, Survival Analysis, Immunity, Humoral, Lymphoma, Surgery, Transplantation, Leukemia, Treatment Outcome, Chemotherapy, Adjuvant, Female, business |
| الوصف: | Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD 19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which randomized 157 patients with B-cell lymphoma in complete remission following autologous transplant to treatment with anti-B4-bR or observation. With a median follow-up time for patients of 5.8 years, the median event-free survival for protocol treatment and observation are 2.1 and 2.9 years, respectively (p = 0.275). The median overall survival for treatment and observation are 6.1 years and not reached, respectively (p = 0.063). Therefore, no differences were found in event-free survival and overall survival between protocol treatment and observation, although there was a trend toward improved survival with observation. These data fail to support a role for anti-B4-bR as consolidative therapy after bone marrow transplant in patients with B-cell lymphoma. |
| تدمد: | 1029-2403 1042-8194 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00d8935c11fa1755d5afceaabb4ec246 https://doi.org/10.3109/10428194.2010.543714 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....00d8935c11fa1755d5afceaabb4ec246 |
| قاعدة البيانات: | OpenAIRE |
PDF full text from Publisher | تدمد: | 10292403 10428194 |
|---|